WESTMINSTER, Colo.,
Jan. 25, 2012 /PRNewswire/ --
GeneThera, Inc. (OTCQB: GTHR) announced today that it has acquired
a majority ownership of Applied Genetics, a molecular diagnostic
company based in Monterrey,
Mexico. Applied Genetics is a molecular diagnostic company
that focuses on commercializing molecular testing for Johne's
disease in Mexico.
This acquisition is part of a broader strategy aimed at quickly
initiating Applied Genetics revenue-generating operation.
Dr. Tony Milici, CEO of GeneThera
and Interim President of Applied Genetics, commented on the news:
"We are very pleased to have reached an agreement with the other
shareholders of Applied Genetics to acquire a controlling interest
in the company. We will continue our efforts to make GeneThera a
leader in molecular diagnostic testing both in Mexico and South
America."
Johne's disease is a global devastating and incurable disease of
dairy cows, sheep, and goats caused by a bacterium called
Mycobacterium Paratuberculosis sub. Avium, (MAP). An
overwhelming number of studies have shown that MAP is the causative
agent of Crohn's disease in humans. Dairy products, contaminated
with MAP, are the vehicles by which the infection spreads in the
human intestine. Applied Genetics employs the use of GeneThera
HerdCheck™ to test and control the spread of Johne's disease in
Mexico. HerdCheck™ is a proprietary molecular diagnostic
system based on the use of high throughput robotics and Real time
PCR.
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company
located in Westminster, Colorado.
The Company's proprietary diagnostic solution is based on a genetic
expression assay, GES™ and Johne's disease management system,
HERDCHECK™, designed to function on a highly automated Fluorogenic
PCR platform. This platform enables GeneThera to offer tests that
are presently not available from other technologies. The GES™ and
HERDCHECK™ systems are designed for a host of individual diseases,
the current priority being Johne's disease.
This press release contains forward-looking statements, which
are made pursuant to the Safe-Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as "intends,"
"believes," and similar expressions reflecting something other than
historical fact are intended to identify forward-looking
statements, but are not the exclusive means of identifying such
statements. These forward-looking statements involve a number of
risks and uncertainties, including the timely development and
market acceptance of products and technologies, the ability to
secure additional sources of finance, the ability to reduce
operating expenses, and other factors described in the Company's
filings with the Securities and Exchange Commission. The actual
results that the Company achieves may differ materially from any
forward-looking statement due to such risks and uncertainties. The
Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
For more information, contact Dr. Tony
Milici at 720- 439-3011. http://www.genethera.net
GeneThera, Inc.
SOURCE GeneThera, Inc.